Disease

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Disease Recent News

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?

Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.

Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine

Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions.

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients

Cartesian reports 12-month data for Descartes-08 in myasthenia gravis; Phase 3 AURORA trial expected to begin in Q2 2025.

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.

Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Why Is Portage Biotech Stock Skyrocketing Friday?

Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors

Exelixis' Cabometyx gains FDA approval for advanced neuroendocrine tumors, while phase 3 data confirms sustained survival benefits in renal cancer.

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.

Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough

JNJ stock hits Golden Cross, signaling potential long-term upside. Latest breakthrough in lung cancer treatment could provide additional catalyst.

Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.

AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients

AbbVie's Elahere maintains strong efficacy in the Phase 3 MIRASOL trial for ovarian cancer, with durable survival benefits and consistent safety data.

Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025

Avidity's del-zota met key Phase 1/2 trial goals in DMD44, shows strong exon skipping, dystrophin restoration and creatine kinase reduction.

Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested in its Phase 1 trial.

Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment

Scholar Rock will present new Phase 3 SAPPHIRE trial data on apitegromab at the 2025 MDA conference, highlighting efficacy and safety in SMA treatment.

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Cannabis Takes On Superbugs: Could This New Drug 'Change Infection Treatment Forever'?

A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC and CBG.

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine

According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.

HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets.

GeoVax Labs Stock Surges Ahead Of The Close, Shares Remain Volatile: What's Happening?

GeoVax Labs shares popped ahead of the close on Wednesday and continue to bounce around in extended trading following a report suggesting Wayne County confirmed its first case of mpox since 2022.

FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch

The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.

Mpox Vaccine Maker Bavarian Nordic Targets Broader Access With European Submission For Imvanex Adolescent Use During WHO Emergency

Bavarian Nordic submits data to European Medicines Agency seeking approval to extend Imvanex vaccine use to adolescents. New trials in younger children planned as global demand for smallpox and mpox vaccines rises.